Article
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
AIDS (London, England) - 1 Jun 2012
Lorenzana Sarah B, Hughes Michael D, Grinsztejn Beatriz, Collier Ann C, Luz Paula Mendes, Freedberg Kenneth A, Wood Robin, Levison Julie H, Mugyenyi Peter N, Salata Robert, Wallis Carole L, Weinstein Milton C, Schooley Robert T, Walensky Rochelle P
Abstract excerpt
OBJECTIVES: To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE). METHODS: We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.